What does AESOP Monitor

• AMR rates and resistant phenotypes of community-onset and hospital-onset enterococcal bloodstream infections by jurisdiction.

• Glycopeptide and high-level gentamicin resistant phenotypes by jurisdiction.

• Infection types associated with enterococcal bloodstream infections.

• Outcomes (30-day all-cause mortality, length of stay post-episode) by community- versus hospital-onset, and for vancomycin-susceptible versus vancomycin-resistant enterococci.

• The emergence and spread of vancomycin-resistant Enterococcus faecium clones and van genes in Australia by jurisdiction.

• Trends using data from previous AESOPs by jurisdiction and providing analysis and commentary on the importance of trends for clinical practice and the response to AMR.

Why does it Matter

Vancomycin-resistant enterococci (VRE) cause difficult‑to‑treat hospital infections.

AESOP data:

• Supports hospital stewardship decisions

• Assists infection control responses to VRE outbreaks

• Provides national VRE trends to AURA